Skip to main content

Table 1 Population characteristics

From: Personalized prediction of incident hospitalization for cardiovascular disease in patients with hypertension using machine learning

Characteristics

No. (%), Mean or Median (IQR)

N = 259,873

(899,392.8 person-years)

Percentage (95% CI)

Age in years (Mean ± SD)

56.6 ± 14.0

 

 Median (Q1, Q3)

56.1 (47.2, 65.8)

 

Age groups (years)

 20–49

84,032

32.3 (32.2–32.5)

 50–64

106,526

41.0 (40.8–41.2)

 65–74

42,107

16.2 (16.1–16.4)

 75–99

27,208

10.5 (10.4–10.6)

Sex

 Female

122,233

47.0 (46.8–47.2)

 Male

137,640

53.0 (52.8–53.2)

Region of residence

 Rural

42,669

16.4 (16.3–16.6)

 Urban

217,204

83.6 (83.4–83.7)

Number of Charlson Comorbidities

 0

175,227

67.4 (67.3–67.6)

 1–2

69,443

26.7 (26.6–26.9)

  ≥ 3

15,203

5.9 (5.8–5.9)

Charlson comorbidities

 Peripheral vascular disease

4721

1.8 (1.8–1.9)

 Dementia

5008

1.9 (1.9–2.0)

 Chronic pulmonary disease

38,808

14.9 (14.8–15.1)

 Rheumatologic disease

4849

1.9 (1.8–1.9)

 Peptic ulcer disease

4406

1.7 (1.7–1.8)

 Mild liver disease

5010

1.9 (1.9–2.0)

 Diabetes without chronic complications

20,065

7.7 (7.6–7.8)

 Diabetes with chronic complications

5247

2.0 (2.0–2.1)

 Hemiplegia or paraplegia

525

0.2 (0.2–0.2)

 Renal disease

5344

2.1 (2.0–2.1)

 Any malignancy, including leukemia and lymphoma

17,208

6.6 (6.5–6.7)

 Moderate or severe liver disease

583

0.2 (0.2–0.2)

 Metastatic solid tumor

2294

0.9 (0.9–0.9)

Lab test results

 LDL-cholesterol (> 3.5 mmol/L)

87,633

33.7 (33.5–33.9)

 Blood glucose (≥7.0 mmol/L)

53,337

20.5 (20.4–20.7)

 eGFR (< 60 mL/min/1.73m2)

63,697

24.5 (24.4–24.7)

 HbA1c (≥6.5%)

36,016

13.9 (13.7–14.0)

 At least one lab test

157,934

60.8 (60.6–61.0)

Medications

 Thiazide diuretics

64,248

24.7 (24.6–24.9)

 Beta blockers

47,089

18.1 (18.0–18.3)

 Calcium channel antagonists

62,112

23.9 (23.7–24.1)

 Agents acting on the renin-angiotensin system

174,891

67.3 (67.1–67.5)

 Miscellaneous antihypertensives

5245

2.0 (2.0–2.1)

  ≥ 1 of the medications listed above

209,729

80.7 (80.6–80.9)

 Follow-up years (median (Q1, Q3))

3.6 (2.2, 4.8)

 
  1. Note: CI confidence interval, IRQ interquartile range, Q1 first quartiles, Q3 third quartiles, SD standard deviation, Number of Charlson comorbidities: excluding CVD related comorbidities and HIV/AIDS